PL447175A1 - Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases - Google Patents

Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases

Info

Publication number
PL447175A1
PL447175A1 PL447175A PL44717523A PL447175A1 PL 447175 A1 PL447175 A1 PL 447175A1 PL 447175 A PL447175 A PL 447175A PL 44717523 A PL44717523 A PL 44717523A PL 447175 A1 PL447175 A1 PL 447175A1
Authority
PL
Poland
Prior art keywords
liposomes
active substances
pharmacologically active
treatment
local delivery
Prior art date
Application number
PL447175A
Other languages
Polish (pl)
Inventor
Magdalena PRZYBYŁO
Tomasz Borowik
Marek Langner
Paweł GRIEB
Original Assignee
Lipotech Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotech Spółka Z Ograniczoną Odpowiedzialnością filed Critical Lipotech Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL447175A priority Critical patent/PL447175A1/en
Publication of PL447175A1 publication Critical patent/PL447175A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem wynalazku jest zawiesina liposomów do miejscowego dostarczania substancji farmakologicznie czynnych w leczeniu chorób oczu, charakteryzująca się tym, że liposomy zbudowane są z jednej dwuwarstwy lipidowej zamykającej przestrzeń hydrofilową, przy czym w ich skład wchodzą: co najmniej jeden neutralny związek amfifilowy, co najmniej jeden amfifilowy związek kationowy tworzące dwuwarstwę lipidową, przynajmniej jedna hydrofobowa bądź hydrofilowa substancja farmakologicznie czynna, glikol propylenowy lub gliceryna oraz roztwór wodny. Średnica liposomów mieści się zakresie od 50 nm do 300 nm, a zawartość substancji kationowej nie przekracza 5 mol%. Wynalazek dotyczy również sposobu tworzenia liposomowych nośników z przeznaczeniem do zastosowań okulistycznych i charakteryzujących się wysoką wydajnością zamykania substancji czynnychThe subject of the invention is a liposome suspension for local delivery of pharmacologically active substances in the treatment of eye diseases, characterized in that the liposomes are composed of one lipid bilayer enclosing a hydrophilic space, and their composition includes: at least one neutral amphiphilic compound, at least one cationic amphiphilic compound forming a lipid bilayer, at least one hydrophobic or hydrophilic pharmacologically active substance, propylene glycol or glycerin and an aqueous solution. The diameter of the liposomes is in the range from 50 nm to 300 nm, and the content of the cationic substance does not exceed 5 mol%. The invention also relates to a method of creating liposome carriers intended for ophthalmic applications and characterized by high efficiency of enclosing active substances

PL447175A 2023-12-19 2023-12-19 Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases PL447175A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL447175A PL447175A1 (en) 2023-12-19 2023-12-19 Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447175A PL447175A1 (en) 2023-12-19 2023-12-19 Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases

Publications (1)

Publication Number Publication Date
PL447175A1 true PL447175A1 (en) 2025-06-23

Family

ID=96092924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447175A PL447175A1 (en) 2023-12-19 2023-12-19 Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases

Country Status (1)

Country Link
PL (1) PL447175A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415291A1 (en) * 2001-06-20 2004-05-06 Leapfrog Enterprises, Inc. Interactive apparatus using print media
PL402511A1 (en) * 2013-01-21 2014-08-04 Lipid Systems Spółka Z Ograniczoną Odpowiedzialnością Liposomal formulation of nisin
WO2018172504A1 (en) * 2017-03-23 2018-09-27 Lipid Systems Sp. Z.O.O. High-efficiency encapsulation of hydrophilic compounds in unilamellar liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415291A1 (en) * 2001-06-20 2004-05-06 Leapfrog Enterprises, Inc. Interactive apparatus using print media
PL402511A1 (en) * 2013-01-21 2014-08-04 Lipid Systems Spółka Z Ograniczoną Odpowiedzialnością Liposomal formulation of nisin
WO2018172504A1 (en) * 2017-03-23 2018-09-27 Lipid Systems Sp. Z.O.O. High-efficiency encapsulation of hydrophilic compounds in unilamellar liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONEZ C, VANDENBRANDEN M, RUYSSCHAERT JM: "Prog Lipid Res. 2008 Sep;47(5):340-7.", CATIONIC LIPOSOMAL LIPIDS: FROM GENE CARRIERS TO CELL SIGNALING, DOI: 10.1016/j.plipres.2008.03.002 *

Similar Documents

Publication Publication Date Title
Yeo et al. Niosomes: a review of their structure, properties, methods of preparation, and medical applications
US20230181738A1 (en) Oil-in-water emulsions comprising cetalkonium chloride and methods of making and using the same
US20240307306A1 (en) Microemulsion for ophthalmic drug delivery
Albash et al. Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in-vitro characterization, statistical optimization, and in-vivo assessment
Sahoo et al. Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives
US20230241030A1 (en) Macrogol 15 hydroxystearate formulations
ES2635197T3 (en) Pharmaceutical composition having desirable bioavailability
JP2022541874A (en) Microemulsion composition
JP2004525138A (en) Liposomal compositions for improved intracellular delivery of therapeutic agents
Nath et al. Recent advances in the use of cubosomes as drug carriers with special emphasis on topical applications
ES2906431T3 (en) Composition for eye treatment
JP7587644B2 (en) Lipid particle compositions and pharmaceutical compositions
CN101601648B (en) Sub-microemulsion used for intravenous injection of polyene yew alcohol phospholipid composite and preparation method thereof
JP2007537220A5 (en)
Sanap et al. Ophthalmic nano-bioconjugates: critical challenges and technological advances
CN115919759B (en) A low-aggregate ophthalmic nanoformulation and its preparation method and use
Hendawy et al. Nose-to-Brain Delivery of Armodafinil Loaded Spanlastics in Situ Gel: Formulation, Statistical Optimization, and Pharmacokinetics Evaluation
PL447175A1 (en) Liposomes for local delivery of pharmacologically active substances in the treatment of eye diseases
CN115968278A (en) Lipid-polymer compositions and methods of use
Kumari et al. Formulation Considerations and Application of Nanostructured Lipid Carriers (NLC) for Ocular Delivery.
Ragaey et al. Modernized management of ocular keratitis via nanovesicular drug delivery systems
SINGH et al. Role of nanoemulsion for safe and cost-effective delivery of amphotericin B
Dhumal et al. Development and evaluation of amphiphilic heterolipid based pH-sensitive nanomicelles of doxorubicin
WO2023220003A1 (en) Topical ophthalmic pirfenidone-loaded liposomes to increase the therapeutic activity of the drug in cornea and useful for prevention or therapy of corneal haze
HK1197018B (en) Macrogol 15 hydroxystearate formulations